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bal public health as 33% of the world population is considered
to be infected with Mycobacterium tuberculosis (MTB). Further,
multi-drug-resistant strains of MTB in association with
human immunodeficiency virus (HIV) have further created a
worrying aspect to the TB problem. The current epidemics
of extensively drug-resistant TB have also been an increasing
threat in some regions around the world [1]. Most drug-resis-
tant clinical strains of MTB, are resistant to isoniazid (INH),
one of the most effective anti-TB drugs used for TB treatment
[2]. Since existing TB control methods seem inadequate to
prevent the rise in TB incidence among HIV-infected persons,
the World Health Organization recommends INH preventive
therapy (IPT) for HIV-infected persons as part of the core ser-
vices [3].
Although two recent meta-analyses have shown that there
was more than a 60% reduction in TB in HIV-infected adults
after IPT [4], another meta-analysis study also reported that
INH prophylactic therapy was not so much effective among
young children and that there was little evidence of a mortal-
ity benefit in children of any age [5]. After conducting a sys-
tematic review on IPT and risk for resistant TB, Balcells et
al. [6] suggested that IPT therapy would decrease the number
of reactivated TB cases attributable to INH-susceptible strains
but would have a lesser effect on resistant strains, which
would increase the proportion of resistant strains among sub-
sequent cases of active TB. Further, they suggested that the
presence of active TB should be excluded before IPT, and con-
tinued surveillance for INH resistance is essential [6]. INH is
reported to generate a variety of highly reactive compounds,
such as reactive oxygen species like superoxide, peroxide
and hydroxyl radical, nitric oxide, reactive organic species like
isonicotinicacyl radical or anion, and certain electrophilic
species, which then attack multiple targets in MTB. INH is a
prodrug and requires activation before it becomes therapeuti-
cally effective. This process is carried out by the catalase-
peroxidase activity of the katG gene product, and mutations
in the katG gene contribute to resistance to INH [7].
Bioinformatics studies in our laboratory showed that amutation in katG (S315T/S315N) prevents free radical forma-
tion, thus the development of resistance to the drug [8] and
mutation in N-acetyltranserase enzyme which has an impor-
tant role in acetylating and detoxifying INH, increases the sta-
bility and catalytic ability of the mutant enzyme, thus making
the drug ineffective (unpublished data). As per the TB drug
resistance mutation database, 22 genes/proteins of MTB were
reported to associate with INH resistance [9]. Out of 22 genes/
proteins, 11 genes were reported to be induced by INH [10].
The detailed mechanism of resistance and induction in a
number of proteins is yet to be thoroughly understood.
Thus, there is a need to understand the role of INH inside
the host as well as in MTB in order for the drug to be used
widely in preventive therapy of TB, for the fear that one day
it may not become effective in TB therapy.
INH is not a safe drug and is not without toxicity and side
effects. Adverse effects of INH have been reported by different
researchers based on their clinical studies. INH, alone or in
combination with other anti-TB drugs, mostly associatedwith
toxicity [11]. Acute poisoning leads to lactic acidosis and renal
failure [12], development of agranulocytosis [13], INH-induced
tenosynovitis [14], INH-induced liver injury [15,16], and fatal
INH-induced acute liver failure [17] are a few of the toxic con-
sequences of INH. Furthermore, INH and/or its metabolites
(e.g., hydrazine) may be associated with causing mitochon-
drial injury that may lead to oxidant stress in mitochondria
and destruction of energy homeostasis [15]. Catan˜o and
Morales [18] studied the follow-up results of INH chemopro-
phylaxis during biological therapy in Colombia and observed
that 3.2% of patients developed active TB, and 17.2% of
patients developed intolerance or toxicity related to INH.
Based on their observation they suggested that chemopro-
phylaxis with INH seems to be effective and safe for the pre-
vention of most TB reactivation in individuals with latent TB
infection, but toxicity must be monitored during follow-up
[18]. However, concerns have been raised about the wide
use of INH due to its toxicity, predominantly hepatotoxicity,
as biochemical monitoring is not routinely carried out during
INH therapy [17].
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TB in healthy children and treating latent TB infection in HIV
patients, concerns about the risk for development of
INH-resistant TB with extensive use of INH should be consid-
ered before its widespread use in HIV infection, latent infec-
tion, and in particular in children.
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